Clinical Trial Update: Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating enteral fish oil for cholestasis in infants has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis
• Liver Disease

Drugs mentioned

• Enteral fish oil (omega-3 fatty acids (EPA and DHA))
• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Cholestasis, Liver Disease | Phase 2 | Status: WITHDRAWN